sB7-H4蛋白和CA125联检在卵巢癌患者中的应用价值
Applicative Value of Combined Determination on Serum sB7-H4 Protein and CA125 Levels in Patients with Ovarian Cancer
李春仙 1陈洁 1彭岚1
作者信息
- 1. 宁波大学医学院附属医院医学检验部,315020
- 折叠
摘要
目的:探讨联检血清可溶性B7-H4蛋白(sB7-H4)和CA125水平在卵巢癌诊断中的应用价值.方法:采用ELISA测定51例卵巢癌患者、89例卵巢良性疾病患者和105例健康对照者血清sB7-H4水平,同时测定血清CA125水平,并对结果进行比较分析.结果:卵巢癌组血清sB7-H4、CA125水平均显著高于卵巢良性疾病组和健康对照组,差异有统计学意义(P<0.01);sB7-H4在早期卵巢癌(Ⅰ期～Ⅱ期)阳性率高于CA125,两者联检可提高诊断卵巢癌的敏感性.结论:sB7-H4是一种较好的预测早期卵巢癌的肿瘤标志物,其联检CA125有助于卵巢癌的早期诊断.
Abstract
Objective To explore the applicative value on serum soluble B7-H4 protein and CA12S levels in patients with ovarian cancer. Methods sB7-H4 was determined by ELISA in ovarian cancer patients (re =51) , benign ovarian disease patients (n = 89) and healthy controls (n = 105) , serum CA125 was detected simultaneously also made a comparative analysis of the results. Results The levels of sB7-H4 and CA125 were significantly higher in ovarian cancer group than that in benign ovarian disease group and healthy control group,the difference indicated remarkable(P <0.01) ,there were no significant difference between the benign ovarian disease group and healthy control group. The positive rate of sB7-H4 level manifested higher than CA125 in the early ovarian malignancies. The simultaneous determination showed the higher diagnostic sensitivity. Conclusion sB7-H4 can be a usefull tumor biomarker in prognostic of early ovarian cancer, it combined with CA125 might be helpful in the definite early diagnosis of ovarian cancer.
关键词
卵巢癌/sB7-H4蛋白/糖类抗原125Key words
ovarian cancer/sB7-H4protein/CA125引用本文复制引用
出版年
2013
NETL
NSTL
维普
万方数据